Lercapin Ace

Enalapril Maleate and Lercanidipine Hydrochloride, the active ingredients in Lercapin Ace, are an ACE inhibitor and a calcium‑channel blocker presented as an oral tablet for oral use. They treat hypertension in adult patients by lowering systemic blood pressure.

GNH USA supplies Lercapin Ace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Lercapin Ace, a fixed‑dose antihypertensive combination, acts on the renin‑angiotensin system and vascular smooth‑muscle calcium channels to control elevated blood pressure.

- Hypertension: reduces both systolic and diastolic blood pressure in adults with primary hypertension. - Essential hypertension: provides effective blood pressure control when monotherapy is insufficient. - Secondary hypertension (adjunct): used as an add‑on therapy to achieve target blood pressure in patients with secondary causes.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness or light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Flushing: transient warmth and redness of the skin. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue, or airway. - Severe hypotension: marked drop in blood pressure causing faintness. - Hepatic dysfunction: abnormal liver enzyme elevations. - Hyperkalemia: elevated potassium levels in blood. - Renal impairment: worsening kidney function. - Allergic reactions: rash, itching, or severe skin eruptions.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for adverse events. - Blood pressure monitoring: regularly assess to ensure therapeutic targets are met. - Renal function assessment: check serum creatinine and eGFR before and during treatment. - Electrolyte balance: monitor potassium levels, especially if combined with potassium‑sparing agents. - Pregnancy caution: avoid use during pregnancy due to potential fetal toxicity. - Drug‑specific contraindications: do not co‑administer with aliskiren in patients with diabetes. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercapin Ace may interact with several concomitant medicines, requiring careful management.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise lercanidipine plasma levels. - Beta‑blockers: combined use can lead to excessive bradycardia or hypotension. - Lithium: ACE inhibition can raise lithium concentrations, increasing toxicity risk.